secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001193125-22-308395
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno secures up to $60M financing from Nantahala, Abingworth, Vivo Capital for DCCR
--------------------------------------------------------------------------------

- $10M at closing upon enrollment completion of Study C602; $15M upon positive top-line data; $35M upon FDA approval.
- Warrants for 22.6M shares at avg $2.65, significant premium to Dec 16 close of $0.91.
- Investors include Nantahala Capital, Abingworth, and new investor Vivo Capital.
- Study C602 enrollment on track; U.K. sites expected to initiate shortly.
- Proceeds to support NDA filing and commercial readiness for DCCR in Prader-Willi syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312522308395/0001193125-22-308395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312522308395/d393394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-308395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer